Abstract
To the Editor.—
I have just completed reading the article published in Pediatrics on the live, attenuated varicella vaccine (Varivax), written by the groups from Merck Sharp & Dohme and Biogen Incorporated.1 I was quite impressed with their clinical data concerning the relatively small number of acute side effects and the apparent immunogenicity of the vaccine. Although I'm sure that more studies are in progress, on the basis of the above data, one would think that United States licensure should be right around the corner.
- Copyright © 1992 by the American Academy of Pediatrics
Individual Login
Log in
You will be redirected to aap.org to login or to create your account.
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.